AnaptysBio (ANAB) PT Lowered to $60 at UBS Following Spinoff of Biopharma Business
Tweet Send to a Friend
UBS analyst Michael Yee lowered the price target on AnaptysBio (NASDAQ: ANAB) to $60.00 (from $90.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
